Abstract: Chronic inflammation is a fundamental driver in the pathogenesis and progression of cardiovascular diseases (CVDs), including atherosclerosis, heart failure, and myocarditis. The NOD-like receptor protein 3 (NLRP3) inflammasome has emerged as a critical mediator of this sterile inflammatory response, sensing danger signals such as cholesterol crystals and reactive oxygen species to trigger the release of pro-inflammatory cytokines like interleukin-1β (IL-1β) and IL-18. MCC950 (also known as CRID3) is a potent, highly selective small-molecule inhibitor of the NLRP3 inflammasome. Preclinical studies have demonstrated its robust pharmacological efficacy in ameliorating cardiac hypertrophy, fibrosis, atherosclerosis, and arrhythmias. Mechanistically, MCC950 directly binds to the NACHT domain of the NLRP3 protein, specifically targeting the Walker B ATP-hydrolysis motif, thereby locking the inflammasome in an inactive conformation and preventing the oligomerization of the ASC adaptor protein. Despite its promising therapeutic profile, the clinical translation of MCC950 was halted during Phase II trials due to dose-dependent hepatotoxicity, largely attributed to its furan ring structure. Nevertheless, MCC950 remains a vital pharmacological tool and a foundational structural scaffold for the rational design of next-generation, safer NLRP3 inhibitors aimed at managing high-risk cardiovascular patients.
1. Introduction
Chronic inflammation is increasingly recognized as a primary mechanism involved in the onset and progression of cardiovascular diseases (CVDs), including atherosclerosis, heart failure, atrial fibrillation, and pericarditis [1]. This sustained inflammatory process is largely driven by inflammasomes, which are intracellular multiprotein complexes that act as sensors for pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) [1]. Among these, the NOD-like receptor protein 3 (NLRP3) inflammasome is the most extensively characterized. Upon activation by stimuli such as cholesterol crystals, mitochondrial dysfunction, and reactive oxygen species (ROS), NLRP3 recruits the adaptor protein ASC and procaspase-1, leading to the maturation and secretion of the highly pro-inflammatory cytokines interleukin-1β (IL-1β) and IL-18, as well as inducing a form of inflammatory cell death known as pyroptosis [1] [5] [6].
Given the central role of the NLRP3 inflammasome in cardiovascular pathology, it has become a highly desirable therapeutic target. While early anti-inflammatory strategies focused on downstream cytokine blockade (e.g., IL-1 inhibitors like anakinra and canakinumab), direct inhibition of the NLRP3 complex offers a more specific and upstream approach [1]. MCC950 (originally known as CRID3) was identified as a groundbreaking, potent, and selective small-molecule inhibitor of the NLRP3 inflammasome [4] [10]. This review synthesizes current knowledge on the pharmacological activity, molecular mechanisms, structure-activity relationships, and clinical limitations of MCC950 in the context of cardiovascular diseases.
2. Pharmacological Activity
MCC950 has demonstrated profound efficacy across a wide spectrum of preclinical cardiovascular and inflammatory disease models by specifically blunting NLRP3-driven pathology.
Heart Failure and Cardiac Remodeling: In models of heart failure, MCC950 provides significant cardioprotection. In obese mice subjected to pressure overload (transverse aortic constriction), MCC950 significantly reduced cardiac hypertrophy and fibrosis, ameliorated cardiac metabolism, lowered pulmonary artery pressure, and reduced ventricular arrhythmias [1]. Furthermore, it decreased overall cardiac inflammation and promoted the infiltration of reparative M2 macrophages into cardiac tissues [1].
Myocarditis: In experimental animal models of myosin peptide-induced myocarditis, treatment with MCC950 (10 mg/kg daily) mitigated myocarditis-induced calcium leakage, improved left ventricular ejection fraction (LV-EF), and reduced the frequency of premature ventricular contractions, indicating that NLRP3 inhibition can prevent adverse cardiac remodeling and arrhythmogenesis [2].
Atherosclerosis and Hypertension: The NLRP3 inflammasome is a critical modulator of atherosclerosis, where it is activated by cholesterol crystals to promote plaque instability [1]. MCC950 has been shown to hinder atherosclerosis development by attenuating inflammation and macrophage pyroptosis [8]. Additionally, in models of hypertension induced by salt and deoxycorticosterone acetate, MCC950 effectively reversed elevated blood pressure by inhibiting inflammasome activation and subsequent IL-1β production [4].
3. Molecular Mechanism of Action
MCC950 is a direct and highly selective inhibitor of the NLRP3 inflammasome. Unlike broad-spectrum anti-inflammatory agents, MCC950 specifically targets the NLRP3 protein without affecting the activation of other inflammasomes, such as AIM2, NLRC4, or NLRP1 [4] [5] [8]. It is capable of blocking both canonical and non-canonical pathways of NLRP3 activation [4].
Mechanistically, MCC950 interacts directly with the NACHT domain of the wild-type NLRP3 protein [1] [5]. Detailed biochemical and structural studies have revealed that MCC950 specifically targets the Walker B motif (an ATP-hydrolysis motif) within this NACHT domain [5] [6] [7]. By binding to this site, MCC950 inhibits the ATPase activity of NLRP3, which is a vital step for inflammasome activation [1] [8]. Structurally, MCC950 functions by closing the active conformation of NLRP3, trapping the protein in an inactive state [7] [10]. This conformational lock prevents NLRP3 from adopting the oligomerized state necessary to recruit the adaptor protein ASC, thereby completely blocking ASC oligomerization (speck formation) and the subsequent cleavage of procaspase-1 into its active form [4] [7] [10].
4. Structure-Activity Relationship (SAR)
MCC950 belongs to a class of diarylsulfonylurea-containing compounds (also referred to as cytokine release inhibitory drugs, or CRIDs) [4] [5] [10]. The structural backbone of MCC950 provides several key features that dictate its interaction with the NLRP3 NACHT domain:
Sulfonylurea Group: The sulfonylurea moiety is a critical functional group that is hypothesized to form essential hydrogen bonds with specific amino acids within the active site of the NLRP3 NACHT domain [10].
Tricyclic Ring System: MCC950 features a tricyclic ring system that shapes the steric profile required for precise interaction within the NLRP3 active site. The aromatic nature of these rings enables π–π stacking interactions, which significantly stabilize the inhibitor-target complex [10].
Furan Group: The molecule contains a furan ring, which, while contributing to its binding efficacy, has been identified as a major structural liability associated with the compound's off-target toxicity profile [3] [10].
5. Current Limitations
Despite its exceptional potency and selectivity in preclinical models, the transition of MCC950 into clinical practice has faced insurmountable hurdles. The primary limitation of MCC950 is its safety profile. During Phase II clinical trials for rheumatoid arthritis, the clinical development of MCC950 was abruptly terminated due to severe hepatotoxicity [7] [10]. Patients receiving high-dose administration (approximately 1200 mg daily) exhibited significant transaminase elevations, signaling drug-induced liver injury [7].
This hepatotoxicity is structurally attributed to the presence of the furan group in the MCC950 molecule, as well as potential off-target effects related to carbonic anhydrase inhibition [3] [10]. Furthermore, studies suggest that MCC950 may only be effective against inflammation driven by wild-type NLRP3; it showed reduced binding and failed to inhibit inflammatory pathology in certain disease models driven by specific CAPS-related NLRP3 mutants [5]. These factors highlight that MCC950 possesses a narrow therapeutic window and incomplete inhibitory effects under certain physiological or mutant conditions [3] [6].
6. Future Perspectives
The clinical failure of MCC950 represented a setback, but it provided invaluable mechanistic insights and structural blueprints for the field of inflammasome therapeutics [7]. MCC950 established the proof-of-concept that direct, specific inhibition of the NLRP3 NACHT domain is pharmacologically viable. Consequently, MCC950 serves as the foundational scaffold for the rational design of next-generation inhibitors [10].
Current drug discovery efforts are heavily focused on scaffold hopping and bioisosteric replacement to eliminate the toxic furan group while retaining the potent sulfonylurea and tricyclic ring interactions. For example, compounds like GDC-2394 replaced the furan group with aryl and heteroaryl groups to reduce liver toxicity, though challenges remain [10]. Other novel compounds, such as dapansutrile (OLT1177), have successfully navigated Phase I and II trials by utilizing different chemical structures (e.g., β-sulfonyl nitriles) and incorporating strict dose-selection protocols learned directly from the MCC950 experience [6] [7].
Moving forward, the development of safer, non-sulfonylurea small molecules and the use of machine learning to predict novel NLRP3 inhibitors hold great promise [3] [7]. As the role of the NLRP3 inflammasome in cardiovascular diseases becomes further elucidated, achieving safe and effective targeted therapies will open new avenues for the precision management of high-risk cardiovascular patients suffering from atherosclerosis, heart failure, and myocarditis [1].
